News
HTGM
0.3875
-11.93%
-0.0525
BRIEF-HTG Molecular Diagnostics Inc Says Received Nasdaq Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing
Reuters · 11/18 21:50
HTG Molecular Diagnostics Received Notice From Nasdaq That Co. Does Not Satisfy One Of Nasdaq's Continued Listing Requirement In Nasdaq Stock Market Rule 5550(b)
Benzinga · 11/18 21:13
HTG Molecular GAAP EPS of -$0.41 beats by $0.13, revenue of $1.25M misses by $1.58M
Seekingalpha · 11/11 03:56
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 21.15% and 44.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/10 23:35
HTG Molecular Diagnostics Q3 EPS $(0.41) Up From $(0.60) YoY, Sales $1.25M Down From $2.52M YoY
Benzinga · 11/10 21:42
BRIEF-Htg Molecular Diagnostics Reports Third Quarter 2022 Results
Reuters · 11/10 21:34
BRIEF-HTG To Collaborate With Omicure, Providing Transcriptomic Data Across Several Cancer Indications
Reuters · 10/26 12:42
HTG Provides Update On Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery, Says Completed Planned Milestones For Q3'22
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, completed its planned milestones for the third
Benzinga · 10/12 20:11
HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz., Oct. 12, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, completed its planned milestones for ...
GlobeNewswire · 10/12 20:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 10/11 21:57
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Ontrak (NASDAQ:OTRKP) shares increased by 28.8% to $2.1 during Monday's pre-market session.
Benzinga · 09/26 12:53
HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will...
GlobeNewswire · 09/26 12:00
HTG Molecular Diagnostics, Inc. (HTGM) Moves to Buy: Rationale Behind the Upgrade
HTG Molecular Diagnostics, Inc. (HTGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 09/21 16:00
The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test
TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Institu...
GlobeNewswire · 09/20 20:05
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Gainers
Benzinga · 09/16 08:38
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
Benzinga · 09/15 17:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 09/15 12:26
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Enochian BioSciences (NASDAQ:ENOB) shares moved upwards by 27.8% to $2.3 during Wednesday's after-market session. The market value of their outstanding shares is at $121.7 million.
Benzinga · 09/14 21:35
--HC Wainwright Adjusts Price Target on HTG Molecular Diagnostics to $2 From $3, Reiterates Buy Rating
--HC Wainwright Adjusts Price Target on HTG Molecular Diagnostics to $2 From $3, Reiterates Buy Rating
MT Newswires · 08/15 08:27
More
Webull provides a variety of real-time HTGM stock news. You can receive the latest news about Htg Molecular Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HTGM
HTG Molecular Diagnostics, Inc. is a life science company, which is focused on advancing precision medicine through its transcriptome-wide profiling technology. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation.